# Avita Medical (RCEL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RCEL
## Company Profile
- Ticker: RCEL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 8.12 USD
- Market cap: 128954326.91000001 USD
- Last updated: 2026-08-12
## Business Overview
### Acute Wound Care Company
AVITA Medical provides therapies for acute wound care that support wound closure and patient recovery. Its core RECELL platform uses a patient’s own skin to prepare Spray-On Skin Cells for the treatment of thermal burns and traumatic wounds.
### RECELL and Wound Matrix Portfolio
RECELL is FDA-approved in the United States for thermal burns and trauma wounds. AVITA also holds exclusive U.S. marketing, sales, and distribution rights to the Cohealyx collagen-based dermal matrix and manufacturing and commercialization rights to the PermeaDerm biosynthetic wound matrix.
### Point-of-Care Autologous Treatment
The RECELL system prepares a suspension of a patient’s own skin cells at the point of care. The approach is intended to treat a larger wound area from a smaller donor-skin sample and complement grafting and wound-matrix products.
### International Access and Emergency Preparedness
RECELL or RECELL GO has regulatory access in markets including Europe, Australia, New Zealand, and Japan. The company also has a BARDA contract supporting U.S. burn emergency preparedness.
## Why The Stock Is Moving

As of Aug 12, 2026, RCEL closed down 0.98% at $8.12. No new same-company headline was identified in the current news window.

## Future Catalysts

- Additional complete data from Cohealyx I will further assess the product’s ability to shorten the time required for wound-bed readiness before skin grafting.
- Following approval of RECELL GO in Australia and New Zealand, regional commercial rollout is the next product-expansion milestone.

## Recent News
- 2026-08-09 22:00 EST — [AVITA Medical to Host Investor Webinar Briefing](https://biopharmsignal.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-0b84f363) — Source: Avita Medical
- 2026-08-07 12:45 EST — [AVITA Medical Announces Participation at Canaccord Genuity Growth Conference](https://biopharmsignal.com/news/RCEL/avita-medical-announces-participation-at-canaccord-genuity-growth-conference-d565c588) — Source: Avita Medical
- 2026-08-06 20:02 EST — [AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven](https://biopharmsignal.com/news/RCEL/avita-medical-reports-second-quarter-results-raises-2026-revenue-guidance-and-ex-2f35a8f6) — Source: Avita Medical
- 2026-07-14 20:05 EST — [AVITA Medical to Announce Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RCEL/avita-medical-to-announce-second-quarter-2026-financial-results-8e67c186) — Source: Avita Medical
- 2026-06-18 12:40 EST — [AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting](https://biopharmsignal.com/news/RCEL/avita-medical-highlights-first-u-k-clinical-experience-with-recell-go-at-british-188835be) — Source: Avita Medical